John G. Houston Sells 31,338 Shares of Arvinas, Inc. (NASDAQ:ARVN) Stock

by · The Markets Daily

Arvinas, Inc. (NASDAQ:ARVN – Get Free Report) CEO John G. Houston sold 31,338 shares of the business’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $16.72, for a total transaction of $523,971.36. Following the sale, the chief executive officer now directly owns 1,157,480 shares in the company, valued at $19,353,065.60. This trade represents a 2.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Arvinas Price Performance

ARVN opened at $17.08 on Thursday. The firm has a fifty day moving average price of $18.38 and a 200 day moving average price of $22.76. Arvinas, Inc. has a 1 year low of $16.07 and a 1 year high of $51.51. The stock has a market cap of $1.17 billion, a P/E ratio of -6.16 and a beta of 1.88.

Arvinas (NASDAQ:ARVN – Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same period in the previous year, the business earned ($2.53) earnings per share. Equities analysts expect that Arvinas, Inc. will post -3.81 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. BMO Capital Markets reaffirmed an “outperform” rating and set a $82.00 price target (down previously from $88.00) on shares of Arvinas in a research report on Wednesday, February 12th. HC Wainwright reaffirmed a “buy” rating and set a $87.00 target price on shares of Arvinas in a report on Wednesday, December 11th. Stephens assumed coverage on shares of Arvinas in a report on Monday, November 18th. They issued an “overweight” rating and a $55.00 price target on the stock. BTIG Research began coverage on shares of Arvinas in a research report on Tuesday, December 10th. They set a “buy” rating and a $69.00 price target for the company. Finally, Guggenheim reaffirmed a “buy” rating and issued a $57.00 price objective on shares of Arvinas in a report on Wednesday, February 12th. Twelve analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $60.00.

Check Out Our Latest Analysis on ARVN

Hedge Funds Weigh In On Arvinas

A number of large investors have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. grew its holdings in Arvinas by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock valued at $61,000 after purchasing an additional 440 shares during the period. Invesco Ltd. lifted its position in shares of Arvinas by 1.6% during the 4th quarter. Invesco Ltd. now owns 37,254 shares of the company’s stock valued at $714,000 after buying an additional 581 shares in the last quarter. Rhumbline Advisers grew its stake in Arvinas by 0.9% in the 4th quarter. Rhumbline Advisers now owns 87,877 shares of the company’s stock valued at $1,685,000 after acquiring an additional 754 shares during the period. Assenagon Asset Management S.A. increased its holdings in Arvinas by 0.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 140,518 shares of the company’s stock worth $2,694,000 after acquiring an additional 777 shares in the last quarter. Finally, Bank of Montreal Can raised its position in Arvinas by 2.7% during the fourth quarter. Bank of Montreal Can now owns 39,407 shares of the company’s stock worth $755,000 after acquiring an additional 1,044 shares during the period. Institutional investors and hedge funds own 95.19% of the company’s stock.

Arvinas Company Profile

(Get Free Report)

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.

Recommended Stories